{"generic":"Deferiprone","drugs":["Deferiprone","Ferriprox"],"mono":{"0":{"id":"930027-s-0","title":"Generic Names","mono":"Deferiprone"},"1":{"id":"930027-s-1","title":"Dosing and Indications","sub":[{"id":"930027-s-1-4","title":"Adult Dosing","mono":"<ul><li>Measure the absolute neutrophil count before starting deferiprone and interrupt therapy if neutropenia develops<\/li><li><b>Iron overload, Transfusional - Thalassemia syndrome:<\/b> Initial, 25 mg\/kg ORALLY 3 times daily; MAX 33 mg\/kg ORALLY 3 times daily; round dose to the nearest 250 mg; adjust dose based on patient response and therapeutic goals<\/li><\/ul>"},{"id":"930027-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy have not been established in pediatric patients "},{"id":"930027-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> No adjustment necessary<\/li><li><b>Hepatic impairment, mild or moderate:<\/b> No adjustment necessary<\/li><li><b>Geriatric:<\/b> Start at low end of dosing range.<\/li><li><b>Ferritin:<\/b> Consider temporary interruption of therapy if serum ferritin consistently falls below 500 mcg\/L.<\/li><li><b>Infection:<\/b> Interrupt therapy for infection and monitor absolute neutrophil count more frequently.<\/li><li><b>Neutropenia\/agranulocytosis:<\/b> Hold therapy if absolute neutrophil count falls below 1.5 x 10(9)\/L; do not rechallenge unless the potential benefit outweighs the risk.<\/li><\/ul>"},{"id":"930027-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Iron overload, Transfusional - Thalassemia syndrome<br\/>"}]},"2":{"id":"930027-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Deferiprone can cause agranulocytosis, often preceded by neutropenia, that can lead to serious infections and death. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and weekly on therapy. Interrupt deferiprone therapy if neutropenia or infection develops and monitor the ANC more frequently. Advise patients to report immediately any symptoms indicative of infection.<br\/>"},"3":{"id":"930027-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930027-s-3-9","title":"Contraindications","mono":"Hypersensitivity to deferiprone or any components of the formulation <br\/>"},{"id":"930027-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Agranulocytosis, sometimes fatal and often preceded by neutropenia, has been reported; monitoring recommended; interruption or discontinuation of therapy may be necessary<\/li><li>-- Infection may occur; interruption of therapy may be necessary<\/li><li>Endocrine and Metabolic:<\/li><li>-- Decreases in zinc levels have been reported; monitoring recommended and supplementation may be necessary<\/li><li>Hepatic:<\/li><li>-- Serum ALT elevations have been reported; monitoring recommended and interruption of therapy may be necessary<\/li><li>Reproductive:<\/li><li>-- Pregnancy should be avoided as drug may cause fetal harm<\/li><li>Concomitant use:<\/li><li>-- Concomitant use of drugs associated with neutropenia or agranulocytosis should be avoided<\/li><\/ul>"},{"id":"930027-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930027-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930027-s-4","title":"Drug Interactions","sub":{"1":{"id":"930027-s-4-14","title":"Major","mono":"<ul><li>Diclofenac (theoretical)<\/li><li>Phenylbutazone (theoretical)<\/li><li>Probenecid (theoretical)<\/li><li>Silymarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"930027-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal discomfort, Abdominal pain, Nausea (12.6%), Vomiting (9.8%)<\/li><li><b>Hematologic:<\/b>Neutrophil count abnormal (7.3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (7.5%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (9.8%)<\/li><li><b>Renal:<\/b>Urine color abnormal (14.6% to 39.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart failure, Systemic vasculitis<\/li><li><b>Dermatologic:<\/b>Henoch-Schoenlein purpura<\/li><li><b>Gastrointestinal:<\/b>Rectal hemorrhage<\/li><li><b>Hematologic:<\/b>Agranulocytosis (1.7%), Neutropenia (6.2%), Pancytopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatic fibrosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage, Enteroviral encephalitis, Seizure<\/li><li><b>Renal:<\/b>Renal failure<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><li><b>Other:<\/b>Multiple organ failure, Sepsis<\/li><\/ul>"},"6":{"id":"930027-s-6","title":"Drug Name Info","sub":{"0":{"id":"930027-s-6-17","title":"US Trade Names","mono":"Ferriprox<br\/>"},"2":{"id":"930027-s-6-19","title":"Class","mono":"Heavy Metal Chelator<br\/>"},"3":{"id":"930027-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930027-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930027-s-7","title":"Mechanism Of Action","mono":"Deferiprone is a chelating agent that binds with ferric ions (iron III) to form neutral 3:1 (deferiprone: iron) complexes stable over a large range of pH values.<br\/>"},"8":{"id":"930027-s-8","title":"Pharmacokinetics","sub":[{"id":"930027-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral, 32.5 to 62.5 minutes<\/li><li>Effect of food: delayed Tmax; minimal effect on absorption<\/li><\/ul>"},{"id":"930027-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 1.55 to 1.73 L\/kg<\/li><li>Protein binding: less than 10%<\/li><\/ul>"},{"id":"930027-s-8-25","title":"Metabolism","mono":"Liver: greater than 85% <br\/>"},{"id":"930027-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 0.48 to 0.56 mg\/kg\/day<\/li><li>Renal excretion: 75% to 90% as metabolite<\/li><\/ul>"},{"id":"930027-s-8-27","title":"Elimination Half Life","mono":"1 to 2.5 hours <br\/>"}]},"9":{"id":"930027-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>May give with meals to reduce nausea<\/li><li>Separate administration of deferiprone by at least 4 hours from foods, antacids, and mineral supplements containing polyvalent cations such as aluminum, zinc, calcium, copper, and magnesium.<\/li><\/ul>"},"10":{"id":"930027-s-10","title":"Monitoring","mono":"<ul><li>serum ferritin concentration: every 2 to 3 months to assess body iron stores for efficacy<\/li><li>absolute neutrophil count (ANC); before starting therapy, then weekly during therapy<\/li><li>CBC with differential; weekly for the first year, then every 2 weeks during therapy<\/li><li>serum ALT levels; monthly during therapy<\/li><li>plasma zinc concentrations; during therapy<\/li><\/ul>"},"11":{"id":"930027-s-11","title":"How Supplied","mono":"<b>Ferriprox<\/b><br\/>Oral Tablet: 500 MG<br\/>"},"13":{"id":"930027-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct lactating female patients to avoid breastfeeding during therapy.<\/li><li>Instruct female patients of childbearing potential to avoid getting pregnant during therapy. Immediately notify your physician if you become or plan to become pregnant while receiving treatment.<\/li><li>Drug may cause nausea, abdominal pain or discomfort, vomiting, joint pain, back pain, headache, or discoloration of urine.<\/li><li>Instruct patients to immediately report signs\/symptoms of arrhythmia including palpitations, dizziness, lightheadedness, syncope, or seizure.<\/li><li>Advise patients to immediately report signs\/symptoms of infection including fever, sore throat, or symptoms of influenza. This may be indicative of agranulocytosis.<\/li><li>Inform patients that the first dose should be taken in the morning, second dose should be taken midday, followed by the last dose in the evening. May take with food to reduce nausea<\/li><li>Advise patient there are significant drug-drug interactions for this drug. Consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><li>Instruct patients to have an interval of at least 4 hours between administration of deferiprone and foods, mineral supplements, and antacids that contain polyvalent cations such as iron, aluminum, or zinc.<\/li><li>Counsel patient to take a missed dose as soon as possible. If the next dose is close in proximity, skip the missed dose and take the next regularly scheduled dose. Do not take a double dose.<\/li><\/ul>"}}}